NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center)(NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center))

概要

基本信息

药物类型

通用抗原疫苗、合成肽疫苗、治疗性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [2]

在研适应症-

非在研适应症

输卵管癌卵巢上皮癌原发性腹膜癌+ [1]

原研机构

Memorial Sloan Kettering Cancer Center

在研机构-

非在研机构

Ludwig Institute for Cancer Research Ltd.

最高研发阶段终止临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的临床试验

NCT01810016

/ Terminated临床1期IIT

Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated

This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated. Patients must have had evidence of NY-ESO-1 or LAGE-1 tumor positivity and radiologically measurable disease by the immune-related Response Criteria (irRC). Primary study objectives were to determine the safety and tolerability of the combination and to evaluate humoral and cellular immune response. Secondary objectives were to evaluate tumor response and immunological changes in the tumor microenvironment.

开始日期2014-01-24

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

NCT00616941

/ Completed临床1期IIT

A Phase 1 Study of NY-ESO-1 Overlapping Peptides With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission

This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer in second or third clinical remission. Study objectives included determination of the safety and immunogenicity following vaccination.

开始日期2008-03-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+1]

NCT00112957

/ Completed临床2期IIT

Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen

This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose tumors expressed NY-ESO-1 or LAGE-1 antigen. Study objectives were to evaluate maintenance of remission at 12 months, time to failure of vaccine therapy, cellular and humoral immunity and any correlation with time to failure, and safety.

开始日期2004-12-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+1]

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的专利（医药）

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不可切除的黑色素瘤	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2014-01-24
不可切除的黑色素瘤	临床1期	澳大利亚	Ludwig Institute for Cancer Research Ltd.	2014-01-24
输卵管癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-01
卵巢上皮癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-01
原发性腹膜癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01810016 (P366, SITC2019)	临床1期	黑色素瘤 NY-ESO-1+	8	IPI + NY-ESO-1 protein + pICLC + Montanide	淵壓鏇獵蓋憲糧衊憲觸(鹽糧鑰觸窪鹽衊醖壓鏇) = 襯網齋齋壓膚壓蓋壓襯壓積選餘積淵糧膚製鏇 (觸衊襯鏇窪膚繭蓋夢積 ) 更多	积极	2019-11-01
				IPI + NY-ESO-1 OLP4 + pICLC + Montanide	淵壓鏇獵蓋憲糧衊憲觸(鹽糧鑰觸窪鹽衊醖壓鏇) = 範積築願製衊願鹹簾蓋壓積選餘積淵糧膚製鏇 (觸衊襯鏇窪膚繭蓋夢積 ) 更多
NCT01810016 (P366, CTgov)	临床1期	不可切除的黑色素瘤	8	Arm A (Arm A (Ipi, NY-ESO-1 Protein))	網鑰淵獵網襯鏇積醖鏇(觸網廠繭積艱鏇齋築網) = 窪夢淵膚鑰鏇淵遞遞簾積簾繭繭窪觸鏇夢齋鑰 (積築願構鹹膚憲遞夢積, 窪鏇廠網壓鑰鹹餘鏇簾 ~ 窪糧壓顧鹽憲艱顧壓築) 更多	-	2018-11-30
				Ipi+NY-ESO-1 OLP4 (Arm B (Ipi, NY-ESO-1 OLP4))	網鑰淵獵網襯鏇積醖鏇(觸網廠繭積艱鏇齋築網) = 夢憲鑰膚鬱壓選壓鬱積積簾繭繭窪觸鏇夢齋鑰 (積築願構鹹膚憲遞夢積, 醖觸構憲憲願鹹糧醖簾 ~ 顧選網艱顧鏇獵構選襯) 更多
NCT00616941 (CTgov)	临床1期	原发性腹膜癌 \| 卵巢上皮癌 \| 输卵管癌	28	NY-ESO-1 OLP4 (Cohort 1)	築願鏇蓋顧鹹顧積構觸(蓋範鏇糧構鹹襯鏇鹽餘) = 艱蓋獵齋願願膚遞遞獵構遞蓋膚簾糧鏇鬱淵鑰 (艱蓋齋夢鹹憲構窪齋衊, 膚遞蓋選鬱顧觸膚網遞 ~ 願齋範繭鏇鏇鹽鏇憲範) 更多	-	2018-07-27
				NY-ESO-1 OLP4 + Montanide (Cohort 2)	築願鏇蓋顧鹹顧積構觸(蓋範鏇糧構鹹襯鏇鹽餘) = 蓋網範簾願襯壓鑰窪鬱構遞蓋膚簾糧鏇鬱淵鑰 (艱蓋齋夢鹹憲構窪齋衊, 壓鬱夢繭醖夢壓餘築艱 ~ 觸構獵願窪鹽鏇觸鏇積) 更多
NCT00112957 (CTgov)	临床2期	原发性腹膜癌 \| 卵巢癌 \| 输卵管癌	23	rV-NY-ESO-1 vaccine	淵艱壓憲醖鑰觸選壓蓋(齋餘蓋簾膚膚簾窪艱獵) = 糧獵製糧願襯獵廠夢鑰範遞淵鏇觸鹽憲遞簾鏇 (製鑰糧艱築憲醖淵選餘, 餘蓋襯選窪齋鹽鏇膚齋 ~ 觸獵網壓製憲襯糧鏇廠) 更多	-	2018-03-19